nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2024-01-24. See notice: 10.1155/2024/9870248.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-23A849F9·Framework v5.0·Pipeline v0.4·Evaluated 21 May 2026·OECD: 3.2 Clinical medicine·Subfield: Radiology, Nuclear Medicine and Imaging·Basis: Full text·Type: Cross-sectional study

Predictive Value of Preoperative Dynamic Contrast-Enhanced MRI Imaging Features in Breast Cancer Patients with Postoperative Recurrence Time.

Wu et al.Wu, Gao, Yao et al.·2022·Emergency medicine international·10.1155/2022/9556880 ↗

In brief

Exploratory DCE-MRI recurrence-timing study undermined by a recurrent-only sample design that inflates apparent predictive performance.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

Although the implementation of surgery has reduced the mortality of breast cancer, postoperative recurrence is still an important problem bothering patients. DCE-GMRI can not only clearly display the morphological characteristics of breast lesions but also dynamically observe the blood perfusion of the lesions. On account of this, we explored the predictive value of preoperative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) imaging features in breast cancer patients on postoperative recurrence time of breast cancer. The results showed that DCE-MRI images can clearly show the hemodynamic characteristics and morphological characteristics of tumor lesions, and have important value in predicting the recurrence time of breast cancer after surgery. The prognosis of early recurrence of breast cancer is worse. DCE-MRI can predict the time of postoperative recurrence and provide important clinical references.

Strengths · Limitations

Strengths

#contribution

Clinically relevant question with structured imaging assessment

The study addresses the practical clinical problem of predicting breast cancer recurrence timing using standardized DCE-MRI with both morphological and hemodynamic parameters measured via Omni-Kinetics software, providing a systematic multi-feature assessment.

↳ Introduction; Section 2.4

#methodological rigour

Survival analysis adds prognostic context

The Kaplan-Meier analysis with log-rank test (P=0.012) demonstrates that early recurrence is associated with worse survival outcomes (median 26.8 vs. 54.3 months), providing clinically meaningful context for the imaging findings.

↳ Section 3.5

#methodological rigour

Quantitative ROC outputs with sensitivity and specificity

The paper reports concrete quantitative metrics including AUC with 95% confidence intervals and sensitivity/specificity at a specified cutoff, enabling comparison with future studies even if the current performance estimates require external validation.

↳ Section 3.4; Table 3

Limitations

#methodological rigour

Recurrent-only sample inflates apparent predictive performance

All 86 patients had confirmed postoperative recurrence — no non-recurrent comparator group is included. The ROC analysis (AUC 0.918) is computed within this restricted population, dramatically inflating discriminative performance compared to what would be observed in a general breast cancer population where the clinically relevant question is who will recur.

↳ Section 2.1; Section 3.4

#methodological rigour

No confounding adjustment for key prognostic factors

The two groups are compared on DCE-MRI features without controlling for tumor stage, grade, or receptor status (ER/PR/HER2) — all known determinants of both recurrence timing and imaging features. No baseline characteristics table stratified by recurrence group is presented.

↳ Methods Sections 2.4–2.6

#reporting

Internal reporting errors undermine confidence

Section 2.1 states '66 patients were divided' but the subgroups sum to 86. Section 3.1 reports 'no significant differences' with '(P < 0.05)', directly contradicting the Discussion which correctly states P > 0.05. These errors suggest insufficient quality control in manuscript preparation.

↳ Section 2.1; Section 3.1; Section 4 (Discussion)

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

The adjudicated quality score is driven primarily by fundamental methodological concerns in study design. The restriction of the sample to patients who already recurred is the most consequential limitation: it means the reported AUC of 0.918 cannot be interpreted as clinical prediction performance in a general breast cancer population. The absence of any confounding adjustment for established prognostic factors (tumor stage, grade, receptor status) further limits interpretability. Internal reporting inconsistencies — including a numerical error in the sample description and an inverted P-value statement in the Results — raised concerns about manuscript preparation quality, though these do not invalidate the core directional findings. The paper's context score reflects a limitations section that acknowledges only sample size while omitting the more fundamental design constraints. The impact potential assessment converged around 2.1, reflecting agreement that the work is at an early exploratory stage without a clear path to clinical implementation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.3±0.2

Contribution
2.8

The paper addresses a clinically relevant question — whether preoperative DCE-MRI features differentiate early from late breast cancer recurrence — extending prior work from recurrence presence to recurrence timing. However, the advance is incremental given the small single-center sample and the abstract overclaims relative to the exploratory design.

Abstract; Introduction; Section 2.1

have important value in predicting the recurrence time of breast cancer after surgery

Methodological Rigour
2.0

The study is restricted to patients who already recurred (N=86, single center), meaning it cannot assess who will recur — only whether features differ between early and late recurrers. No multivariable adjustment for known confounders (tumor stage, grade, receptor status) is performed, and the ROC model specification is unclear, making the reported AUC of 0.918 uninterpretable as a generalizable predictive metric.

Section 2.1; Section 3.4; Methods Sections 2.4–2.6
Reporting
2.8

The paper follows a conventional and readable structure with detailed MRI protocol description. However, the inverted P-value statement in Section 3.1 ('no significant differences... P < 0.05') would mislead a reader relying on the Results alone, and the numerical inconsistency in Section 2.1 creates confusion about sample composition.

Section 3.1; Section 2.1; Section 3.4

There were no significant differences in BPE, morphology, lesion margin, intralesional enhancement, and TIC between the two groups... (P < 0.05)

Positioning
2.3

Literature engagement is sparse (12–14 references, many general rather than specific to DCE-MRI recurrence prediction). The limitations section acknowledges only small sample size, omitting the fundamental design limitation of the recurrent-only sample and absence of confounding adjustment.

Discussion/Conclusion; Introduction

the shortcoming of this study is that the included samples were small

Reliability

Concerns4 of 4 checks


Internal CoherenceNoted

The paper contains a numerical inconsistency (Section 2.1 states '66 patients' but subgroup totals sum to 86) and a logical contradiction in statistical reporting (Section 3.1 reports 'no significant differences' with 'P < 0.05', contradicted by the Discussion which correctly states P > 0.05). Additionally, the ROC analysis (Section 3.4) does not specify which variable or combination of variables produced the reported AUC of 0.918.

Research ConductNoted

No ethics approval or informed consent statement is present in the paper, which is a reporting omission for a retrospective clinical study by 2020 standards. No conflict of interest disclosure is provided. The data availability statement is vague, offering data 'without undue reservation' but naming no repository or persistent identifier.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 14 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2024-01-24. See notice: 10.1155/2024/9870248.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Breast cancer
Type of advanceEmpirical
Route to useNamed
AdvanceConsolidates
BeneficiariesLarge
CitationsNot available
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A single-centre retrospective cohort of only 86 recurrence patients with internal ROC analysis provides proof of concept without independent or prospective validation.

From the paper
“prompt clinicians to prevent and treat in time, thereby improving the survival rate of patients”

The discussion explicitly names clinicians as the actors who would use these imaging predictions to intervene earlier and improve survival.

Pathway

Radiologists and breast oncologists would use preoperative DCE-MRI features to identify patients at high risk of early recurrence and intensify postoperative surveillance and treatment.

Barrier

Evidence rests on 86 patients from one hospital with internal ROC analysis only; external validation and a defined clinical action for predicted early recurrence are lacking.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. How Does Diagnostic Accuracy Evolve with Increased Breast MRI Experience?

    Wu, Alikhassi, Curpen · 2023 · Clinical medicine

    Primary claim

    Diagnostic accuracy improved exponentially with increased MRI experience (definition B, OR of 1.27 and 1.61 for 5 and 10 years, respectively, p = 0.03 for both).

    Tentative
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. General cognitive function and the brain's structural connectome

    Buchanan, Moodie, Batziou, et al. · 2026 · Basic medicine

    Primary claim

    g is supported by a widely distributed white matter network whose macroscopic wiring capacity, microstructural organisation, and age sensitivity contribute in distinct ways.

    Tentative
    Evidence Score
    3.6±0.2
    Reliability
    Caveats
  3. The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network

    Markiewicz, Thompson, Wardlaw, et al. · 2026 · Clinical medicine

    Primary claim

    CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →